Prevención de la fibrilación auricular en el paciente hipertenso

  1. Carlos Escobar Cervantes 1
  2. Alberto Calderón Montero 1
  3. Vivencio Barrios Alonso 1
  1. 1 Hospital Ramón y Cajal
    info

    Hospital Ramón y Cajal

    Madrid, España

    ROR https://ror.org/050eq1942

Revista:
Revista Costarricense de Cardiología

ISSN: 1409-4142

Año de publicación: 2006

Volumen: 8

Número: 2

Páginas: 25-30

Tipo: Artículo

DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Revista Costarricense de Cardiología

Resumen

A large percentage of patients with hypertension are affected by atrial fibrillation (AF). The presence of hypertension increases the risk of AF, a condition which in turn aggravates hypertension. The ability of drugs to interfere with specific signal transduction pathways that facilitate the presence of AF in hypertensive patients is promising. To date, the most effective approach appears to be the inhibition of the renin-angiotensin-aaldosterone system with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs). This approach is under active investigation. Several trials have evaluated the effectiveness of these drugs in the prevention of AF. Data show that both, ACEIs and ARBs appear effective to prevent AF. However, a lack of prospective randomized double-blind trials data limits their application in AF patients without another indication for their use.

Referencias bibliográficas

  • Chobanian, AV,Bakris, GL,Black, HR,Cushman, WC,Green, LA,Izzo, JL. (2003). The Seventh Report of the Joint National Committee: on prevention, detection, evaluation, and treatment of high blood pressure. JAMA. 289. 2560
  • (2003). 2003 European Society of Hypertension European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 21. 1011
  • González-Juanatey, JR,Mazón, P,Soria, F,Barrios, V,Rodríguez-Padial, L,Bertomeu, V. (2003). Actualización (2003) de las guías de práctica clínica de la Sociedad Española de Cardiología en hipertensión arterial. Rev Esp Cardiol. 56. 487
  • Marín, R,Armario, P,Banegas, JR,Campo, C,de la Sierra, A,Gorostidi, M. (2005). Guía española de hipertensión arterial 2005. Hipertension. 22. 1-83
  • MacMahon, S,Peto, R,Cutler, J,Collins, R,Sorlie, P,Neaton, J. (1990). Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 335. 765
  • Kannel, WB,Abbott, RD,Savage, DD,McNamara, PM. (1982). Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 306. 1018
  • Verdecchia, P,Reboldi, G,Gattobigio, R,Bentivoglio, M,Borgioni, C,Angeli, F. (2003). Atrial fibrillation in hypertension: predictors and outcome. Hypertension. 41. 218
  • Hennersdorf, MG,Strauer, BE. (2001). Arterial hypertension and cardiac arrhythmias. J Hypertens. 19. 167
  • Wachtell, K,Hornestam, B,Letho, M,Slotwiner, DJ,Gerdts, E,Olsen, MH. (2005). Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 45. 705
  • Garcia-Acuña, JM,Gonzalez-Juanatey, JR,Alegria, E,Gonzalez, I,Listerri, JL. (2002). La fibrilación auricular permanente en las enfermedades cardiovasculares en España. Estudio CARDIOTENS 1999. Rev Esp Cardiol. 55. 943
  • Fuster, V,Ryden, LE,Asinger, RW,Cannom, DS,Crijns, J,Frye, RL. (2001). ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences. J Am Coll Cardiol. 38. 1231
  • Goette, A,Staack, T,Rocken, C,Arndt, M,Geller, JC,Huth, C. (2000). Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 35. 1669
  • Goette, A,Arndt, M,Rocken, C,Spiess, A,Staack, T,Geller, JC. (2000). Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation. 101. 2678
  • Dostal, DE. (2001). Regulation of cardiac collagen: angiotensin and cross-talk with local growth factors. Hypertension. 37. 841
  • Li, D,Shinagawa, K,Pang, L,Leung, TK,Cardin, S,Wang, Z,Nattel, S. (2001). Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 104. 2608
  • Cardin, S,Li, D,Thorin-Trescases, N,Leung, TK,Thorin, E,Nattel, S. (2003). Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res. 60. 315
  • Gonzalez-Juanatey, JR,Grigorian, L. (2006). Manejo de la fibrilación auricular en el paciente hipertenso. Sociedad Española de Cardiología. Madrid.
  • Ehrlich, JR,Hohnloser, SH,Nattel, S. (2006). Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 27. 512
  • Kalus, J,Coleman, CI,White, CM. (2006). The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol. 46. 21
  • L' Allier, PL,Ducharme, A,Keller, PF,Yu, H,Guertin, MC,Tardif, JC. (2004). Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol. 44. 159
  • Hansson, L,Lindholm, LH,Niskanen, L,Lanke, J,Hedner, T,Nicklason, A. (1999). Effect of angiotensinconverting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 353. 611
  • Hansson, L,Lindholm, LH,Ekbom, T,Dahlof, B,Lanke, J,Schersten, B. (1999). Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet. 354. 1751
  • Wachtell, K,Lehto, M,Gerdts, E,Olsen, MH,Hornestam, B,Dahl, B. (2005). Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 45. 712
  • Devereux, RB,Palmieri, V,Liu, JE,Watchtell, K,Bella, JN,Boman, K. (2002). Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. J Hypertens. 20. 1445
  • Fogari, R,Mugellini, A,Destro, M,Corradi, L,Zoppi, A,Fogari, E. (2006). Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol. 47. 46-50
  • Pizzetti, F,Turazza, FM,Franzosi, MG,Barlera, S,Ledda, A,Maggioni, AP. (2001). Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart. 86. 527
  • Pedersen, OD,Bagger, H,Kober, L,Torp-Pedersen, C. (1999). Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 100. 376
  • Vermes, E,Tardif, JC,Bourassa, MG,Racine, N,Levesque, S,White, M,Guerra, PG,Ducharme, A. (2003). Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 107. 2926
  • Maggioni, AP,Latini, R,Carson, PE,Singh, SN,Barlera, S,Glazer, R. (2005). Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 149. 548
  • Swedberg, K,Pfeffer, M,Coen-Solal, A. (2004). Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: results from the CHARM study (abstr). J Am Coll Cardiol. 43. 222
  • Van Den Berg, MP,Crijns, HJ,Van Veldhuisen, DJ,Griep, N,De Kam, PJ,Lie, KI. (1995). Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail. 1. 355
  • Murray, KT,Rottman, JN,Arbogast, PG,Shemanski, L,Primm, RK,Campbell, WB. (2004). Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm. 1. 669
  • Madrid, AH,Bueno, MG,Rebollo, JM,Marin, I,Pena, G,Bernal, E. (2002). Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. Circulation. 106. 331
  • Ueng, C,Tsai, TP,Yu, WC,Tsai, CF,Lin, MC,Chan, C. (2003). Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J. 24. 2090
  • Healey, JS,Baranchuk, A,Crystal, E,Morillo, CA,Garfinkle, M,Yusuf, S. (2005). Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and antengiosin receptor blockers: a meta-analysis. J Am Coll Cardiol. 45. 1832
  • Julius, J,Kjeldsen, SE,Weber, M,Brunner, HR,Ekman, S,Hansson, L. (2004). Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine. Lancet. 363. 2022
  • Lithell, H,Hansson, L,Skoog, I,Elmfeldt, D,Hofman, A,Olofsson, B. (2003). The Study on Cognition and Prognosis in the Elderly (SCOPE) principal results of a randomized double-blind intervention trial. J Hypertens. 21. 875
  • Lafuente-Lafuente, C,Mouly, S,Longas-Tejero, MA,Mahe, I,Bergmann, JF. (2006). Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 166. 719
  • Teo, K,Yusuf, S,Sleight, P,Anderson, C,Mookadam, F,Ramos, B. (2004). Rationale, design, and baseline characteristics of 2 large, simple randomized trials evaluating telmisartan, ramipril and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). Am Heart J. 14. 52-61
Fuente de los datos: Dialnet